Please Wait...

Hepcidin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Hepcidin is a hormone mainly produced by hepatocytes as a precursor pro-peptide which undergoes proteolytic processing to yield its bioactive form of 25 amino-acids. Hepcidin is a key iron regulatory hormone; it inhibits iron entry into the plasma compartment by promoting the degradation of ferroportin, whose fundamental role is to release iron from tissues into the bloodstream (Nemeth et al., 2004a). Hepcidin accumulates after iron intake and under inflammatory conditions resulting in a decreased iron absorption. Conversely, Hepcidin levels drop in iron deficiency. Indeed, Hepcidin synthesis is transcriptionally regulated by the pro-inflammatory cytokine IL-6 and by iron itself resulting in a feedback regulation (Ganz and Nemeth, 2012; Nemeth et al., 2004b).

Bioclinica Lab employs a manual competitive immunoassay for the measurement of the bioactive form of Hepcidin (Hepcidin-25) in human serum.

Ganz, T., and Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823, 1434–1443.

Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., and Kaplan, J. (2004a). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093.

Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., and Ganz, T. (2004b). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner